雷莫西尤单抗联合帕博利珠单抗对比标准化疗在既往接受免疫治疗的晚期非小细胞肺癌中的II期随机研究-Lung-MAP S1800A
这项II期随机Lung-MAP非匹配子研究纳入既往接受免疫检查点抑制剂和铂类化疗后进展的晚期非小细胞肺癌患者,随机接受雷莫西尤单抗联合帕博利珠单抗(RP)或研究者选择的标准治疗(SOC)。RP组中位总生存期14.5个月,SOC组11.6个月,风险比为0.69(80%CI 0.51-0.92),RP组总生存期显著改善。
要点
- RP组中位OS为14.5个月,SOC组为11.6个月,HR为0.69(80%CI 0.51-0.92)。
- RP组与SOC组研究者评估的无进展生存期和缓解率相似。
- RP组≥3级治疗相关不良事件发生率为42%,SOC组为60%。
核心结论
- 这项随机II期试验显示,在既往接受免疫治疗和化疗的晚期非小细胞肺癌患者中,RP较SOC显著改善总生存期。
- 安全性特征与两种药物已知毒性一致。
- 这些数据需进一步评估。
研究设计与样本
- 随机II期Lung-MAP非匹配子研究(S1800A)。
- 纳入不符合生物标志物匹配子研究条件、既往接受ICI和铂类化疗、且在ICI开始后至少84天出现疾病进展的NSCLC患者。
- 随机分配至雷莫西尤单抗联合帕博利珠单抗(RP)组或研究者选择的标准治疗(SOC:多西他赛/雷莫西尤单抗、多西他赛、吉西他滨和培美曲塞)组。
- 目标入组130例可评估患者,主要终点为总生存期,采用单侧10%显著性水平,取标准对数秩检验和加权对数秩检验中较优者。
- 共入组166例患者,其中136例符合条件(RP组69例;SOC组67例)。
主要发现
- RP组总生存期显著改善(风险比[80%CI]:0.69[0.51至0.92];标准对数秩检验单侧P=.05;加权对数秩检验单侧P=.15)。
- RP组中位总生存期(80%CI)为14.5(13.9至16.1)个月,SOC组为11.6(9.9至13.0)个月。
- 大多数亚组中观察到RP的总生存期获益。
- 研究者评估的无进展生存期(风险比[80%CI]:0.86[0.66至1.14];标准对数秩检验单侧P=.25,加权对数秩检验单侧P=.14)和缓解率(RP组22% vs SOC组28%,单侧P=.19)在两组间相似。
- RP组≥3级治疗相关不良事件发生率为42%,SOC组为60%。
局限性
- 这些数据需进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Resistance to immune checkpoint inhibition (ICI) in advanced non-small-cell lung cancer (NSCLC) represents a major unmet need. Combining ICI with vascular endothelial growth factor (VEGF)/VEGF receptor inhibition has yielded promising results in multiple tumor types. METHODS: In this randomized phase II Lung-MAP nonmatch substudy (S1800A), patients ineligible for a biomarker-matched substudy with NSCLC previously treated with ICI and platinum-based chemotherapy and progressive disease at least 84 days after initiation of ICI were randomly assigned to receive ramucirumab plus pembrolizumab (RP) or investigator's choice standard of care (SOC: docetaxel/ramucirumab, docetaxel, gemcitabine, and pemetrexed). With a goal of 130 eligible patients, the primary objective was to compare overall survival (OS) using a one-sided 10% level using the better of a standard log-rank (SLR) and weighted log-rank (WLR; G[rho = 0, gamma = 1]) test. Secondary end points included objective response, duration of response, investigator-assessed progression-free survival, and toxicity. RESULTS: Of 166 patients enrolled, 136 were eligible (69 RP; 67 SOC). OS was significantly improved with RP (hazard ratio [80% CI]: 0.69 [0.51 to 0.92]; SLR one-sided P = .05; WLR one-sided P = .15). The median (80% CI) OS was 14.5 (13.9 to 16.1) months for RP and 11.6 (9.9 to 13.0) months for SOC. OS benefit for RP was seen in most subgroups. Investigator-assessed progression-free survival (hazard ratio [80% CI]: 0.86 [0.66 to 1.14]; one-sided SLR, P = .25 and .14 for WLR) and response rates (22% RP v 28% SOC, one-sided P = .19) were similar between arms. Grade ≥ 3 treatment-related adverse events occurred in 42% of patients in the RP group and 60% on SOC. CONCLUSION: This randomized phase II trial demonstrated significantly improved OS with RP compared with SOC in patients with advanced NSCLC previously treated with ICI and chemotherapy. The safety was consistent with known toxicities of both drugs. These data warrant further evaluation.
引用
- Reckamp KL, Redman MW, Dragnev KH, et al. Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A. J Clin Oncol. 2022. PMID: 35658002. doi:10.1200/JCO.22.00912
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。